Jethro C.C. Kwong, a urology resident from the University of Toronto, discusses a novel artificial intelligence (AI)-based ...

Panelists discuss how survival data from the COMFORT trials support the use of ruxolitinib in myelofibrosis, especially in intermediate- to high-risk patients with significant symptom burden or ...

Levee Medical has begun its pivotal ARID II trial, studying the Voro Scaffold for improved continence after prostatectomy.

A phase 2 study showed that giving maintenance regorafenib could delay disease progression in patients with non-adipocytic ...

Reduced-dose radiotherapy in head & neck cancer shows similar efficacy to standard dose but with lower toxicity, per findings ...

Sophia Kamran, MD, discusses how salvage therapy after biochemical recurrence may improve outcomes for patients with prostate ...

Quoc-Dien Trinh, MD, MBA, discusses a sub-analysis of the phase 3 ARANOTE trial, focusing on Black patients with metastatic ...

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

During a live event, Mark J. Fesler, MD, and participants discussed selection and timing of initiation of JAK inhibitor ...

Oncologists at AUA 2025 share promising data, including sasanlimab, cretostimogene grenadenorepvec, and TAR-200 in NMIBC.

Panelists discuss how posttransplant cyclophosphamide has changed the clinical presentation of chronic graft-vs-host disease (cGVHD), with potentially lower incidence but similar severity when it does ...